BioScrip earnings 'in line' with expectations
By HME News Staff
Updated Fri May 5, 2017
DENVER - BioScrip reported net revenues of $217.8 million for the first quarter of 2017, reflecting a core revenue mix of 72% compared to 60% during the same quarter in 2016. Net loss was $19 million and adjusted EBITD was 5.2 million. For the full year 2017, BioScrip expects to achieve adjusted EBITDA in the range of $45 million to $55 million. “I am pleased with our company's first quarter performance, which was in line with our plan,” said Dan Greenleaf, president and CEO in a press release. “Our sales team met our revenue target for the quarter and continued to increase our core revenue mix.”
Comments